Cargando…

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

BACKGROUND: Oestrogen receptor positive/ human epidermal growth factor receptor positive (ER+/HER2+) breast cancers (BCs) are less responsive to endocrine therapy than ER+/HER2- tumours. Mechanisms underpinning the differential behaviour of ER+HER2+ tumours are poorly characterised. Our aim was to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergamino, Milana A., López-Knowles, Elena, Morani, Gabriele, Tovey, Holly, Kilburn, Lucy, Schuster, Eugene F., Alataki, Anastasia, Hills, Margaret, Xiao, Hui, Holcombe, Chris, Skene, Anthony, Robertson, John F., Smith, Ian E., Bliss, Judith M., Dowsett, Mitch, Cheang, Maggie C.U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482930/ https://www.ncbi.nlm.nih.gov/pubmed/35985932 http://dx.doi.org/10.1016/j.ebiom.2022.104205

Ejemplares similares

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
por: Gao, Qiong, et al.
Publicado: (2019)

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)
por: Bliss, Judith M., et al.
Publicado: (2023)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment
por: Schuster, Eugene F., et al.
Publicado: (2019)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas
por: López-Knowles, Elena, et al.
Publicado: (2016)

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
por: Smith, Ian, et al.
Publicado: (2020)

A poetic story: lessons learnt from the world's largest breast cancer window of opportunity study
por: Bliss, Judith, et al.
Publicado: (2015)

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
por: Ferrando-Díez, Angelica, et al.
Publicado: (2022)

Lights and Shadows in Immuno-Oncology Drug Development
por: Bergamino Sirvén, Milana, et al.
Publicado: (2021)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer
por: Gao, Qiong, et al.
Publicado: (2018)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition
por: López-Knowles, Elena, et al.
Publicado: (2014)

Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
por: Haynes, Ben P., et al.
Publicado: (2021)

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
por: Lopez-Knowles, Elena, et al.
Publicado: (2018)

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic
por: Dowsett, Mitch, et al.
Publicado: (2020)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2019)

Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
por: Barry, Garrett S., et al.
Publicado: (2016)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4
por: Tovey, Sian M, et al.
Publicado: (2006)

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
por: Sirvén, Milana Bergamino, et al.
Publicado: (2019)

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes
por: Watson, Spencer S., et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Expression and clinical significance of HER2/neu, aromatase P450 and adhesion molecule CD24 in endometrial cancer
por: Guan, Liyun, et al.
Publicado: (2023)

Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling
por: Dai, Xiaofeng, et al.
Publicado: (2014)

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
por: Knauer, M, et al.
Publicado: (2010)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2023)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
por: Arpino, Grazia, et al.
Publicado: (2023)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
por: Leary, A, et al.
Publicado: (2006)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_t2jd0qatvtkfju23oa2dnsr3kn